Dr. Hurteau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2650 Ridge Ave
# Kellogg
Evanston, IL 60201Phone+1 847-570-2639Fax+1 847-733-5618
Education & Training
Duke University HospitalFellowship, Gynecologic Oncology, 1992 - 1995
University of Montreal Faculty of MedicineClass of 1985
Certifications & Licensure
IL State Medical License 2002 - 2026- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2014
- Chicago Magazine: Top Doctors Castle Connolly, 2014
- Chicago Magazine - Women's Health Castle Connolly, 2011
- Join now to see all
Clinical Trials
- Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2006 Nov 01
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
- Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
- Join now to see all
Publications & Presentations
PubMed
- 146 citationsBleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group StudyHoward D. Homesley, Brian N. Bundy, Jean A. Hurteau, Lawrence M. Roth
Gynecologic Oncology. 1999-02-01 - 17 citationsExpression and Subcellular Localization of the Cyclin-Dependent Kinase Inhibitor p27Kip1 in Epithelial Ovarian CancerJean A. Hurteau, Bernadette M. Allison, Susan A. Brutkiewicz, Mark G. Goebl, Douglas K. Heilman
Gynecologic Oncology. 2001-11-01 - 430 citationsCombination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyJoyce F. Liu, William T. Barry, Michael J. Birrer, Jung-Min Lee, Ronald J. Buckanovich
The Lancet. Oncology. 2014-10-01
Press Mentions
- The Pro-Apoptotic Actions of 2-Methoxyestradiol Against Ovarian Cancer Involve Catalytic Activation of PKCδ SignalingOctober 6th, 2020
Professional Memberships
- Member
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
